Global Anticoagulant Market 2017-2021




$ 3500

In Stock

About Anticoagulant Market
Anticoagulant prevent clot formations or the enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists; DTIs; and factor Xa inhibitors are among the anticoagulant that are available in the market. They are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi are some of the top vendors in the market.

Technavios analysts forecast the global anticoagulant market to grow at a CAGR of 7.42% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global anticoagulant market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders.

The market is divided into the following segments based on geography:

Technavio's report, Global Anticoagulant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Bayer HealthCare
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Johnson & Johnson

Other prominent vendors
Abbott Vascular
Biosensors International
C. R. Bard

Market driver
Increasing demand for NOACs
For a full, detailed list, view our report

Market challenge
Increasing cost of NOACs
For a full, detailed list, view our report

Market trend
Strategic alliance
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

Market overview
Top-vendor offerings

PART 03: Market research methodology

Research methodology
Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview
Five forces analysis

PART 08: Market segmentation by ROA

Oral anticoagulants
Injectable anticoagulants
PART 09: Market segmentation by drug class
Factor Xa inhibitors
Vitamin K antagonists

PART 10: Market segmentation by application


PART 11: Geographical segmentation

Global anticoagulant market in Americas
Anticoagulant market in EMEA
Anticoagulant market in APAC

PART 12: Market drivers

Increasing demand for NOACs
Growing prevalence of coagulation disorders
Increase in hip and knee surgeries

PART 13: Impact of drivers

PART 14: Market challenges

Increasing cost of NOACs
Lack of antidotes in the market for NOACs
Patent expiry: a threat to market

PART 15: Impact of drivers and challenges

PART 16: Market trends

Strategic alliance
Increasing focus toward emerging economies
Patient assistance programs

PART 17: Vendor landscape

Competitive scenario
Other prominent vendors

PART 18: Key vendor analysis

Bayer HealthCare
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Johnson & Johnson

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio
List of Exhibits

Exhibit 01: Product offerings

Exhibit 02: Process of blood coagulation

Exhibit 03: Mechanism of action (MoA) of anticoagulant

Exhibit 04: Key customer segments of global anticoagulant market

Exhibit 05: Pipeline analysis 2016

Exhibit 06: Key pipeline molecules

Exhibit 07: Global anticoagulant market overview

Exhibit 08: Global anticoagulant market 2016-2021 ($ billions)

Exhibit 09: Five forces analysis

Exhibit 10: Segmentation of anticoagulant market based on ROA

Exhibit 11: Market share of anticoagulant based on ROA 2016

Exhibit 12: Types of heparin

Exhibit 13: Segmentation of anticoagulant market based on drug class

Exhibit 14: Market share of anticoagulant based on drug class 2016

Exhibit 15: Types of factor Xa inhibitors based on MOA

Exhibit 16: Factor Xa inhibitors in global anticoagulant market 2016-2021 ($ billions)

Exhibit 17: Types of DTIs based on MOA

Exhibit 18: DTIs in global anticoagulant market 2016-2021 ($ billions)

Exhibit 19: Global heparin market 2016-2021 ($ billions)

Exhibit 20: Global vitamin K antagonists market in 2016-2021 ($ billions)

Exhibit 21: Market segmentation by application

Exhibit 22: Market segmentation of anticoagulant based on application

Exhibit 23: Anticoagulant market in Americas 2016-2021 ($ billions)

Exhibit 24: Anticoagulant market in EMEA 2016-2021 ($ billions)

Exhibit 25: Anticoagulant market in APAC 2016-2021 ($ billions)

Exhibit 26: Impact of drivers

Exhibit 27: Patents to expire over forecast period

Exhibit 28: Impact of drivers and challenges

Exhibit 29: Competitive structure analysis of global anticoagulant market 2016

Exhibit 30: Competitive analysis of global anticoagulant market

Exhibit 31: Market share analysis 2016

Exhibit 32: Competitive landscape analysis 2016

Exhibit 33: Bayer HealthCare: Key highlights

Exhibit 34: Bayer HealthCare: Strength assessment

Exhibit 35: Bayer HealthCare: Strategy assessment

Exhibit 36: Bayer HealthCare: Opportunity assessment

Exhibit 37: Bayer HealthCare: YoY revenue and growth rate of XARELTO 2013-2015 ($ billions)

Exhibit 38: Boehringer Ingelheim: Key highlights

Exhibit 39: Boehringer Ingelheim: Strength assessment

Exhibit 40: Boehringer Ingelheim: Strategy assessment

Exhibit 41: Boehringer Ingelheim: Opportunity assessment

Exhibit 42: Boehringer Ingelheim: YoY revenue and growth rate of PRADAXA (global) 2013-2015 ($ billions)

Exhibit 43: Bristol-Myers Squibb: Highlights

Exhibit 44: Bristol-Myers Squibb: Strength assessment

Exhibit 45: Bristol-Myers Squibb: Strategy assessment

Exhibit 46: Bristol-Myers Squibb: Opportunity assessment

Exhibit 47: Bristol-Myers Squibb: YoY revenue and growth rate of ELIQUIS (global) 2013-2015 ($ millions)

Exhibit 48: Bristol-Myers Squibb: Geographic segmentation of ELIQUIS 2015

Exhibit 49: Daiichi Sankyo: Key highlights

Exhibit 50: Daiichi Sankyo: Strength assessment

Exhibit 51: Daiichi Sankyo: Strategy assessment

Exhibit 52: Daiichi Sankyo: Opportunity assessment

Exhibit 53: Johnson & Johnson: Strength assessment

Exhibit 54: Johnson & Johnson: Strategy assessment

Exhibit 55: Johnson & Johnson: Opportunity assessment

Exhibit 56: Sanofi: Key highlights

Exhibit 57: Sanofi: Strength assessment

Exhibit 58: Sanofi: Strategy assessment

Exhibit 59: Sanofi: Opportunity assessment

Exhibit 60: Sanofi: YoY revenue and growth rate of LOVENOX (global) 2013-2015 ($ billions)

Exhibit 61: Sanofi: Geographical segmentation of LOVENOX 2016